Clinical trial of UDP-003 for the treatment of atherosclerosis
Latest Information Update: 04 Jan 2023
At a glance
- Drugs UDP-003 (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors Cyclarity Therapeutics
- 28 Sep 2021 New trial record
- 23 Sep 2021 According to an underdog pharmaceuticals, the company expect to begin clinical trials in 2023.
- 04 Jul 2021 According to an Underdog Pharmaceuticals media release, company concluded a successful meeting with the Medicines and Health products Regulatory Agency (MHRA) of the UK.The MHRA supported inclusion of trial participants with asymptomatic, stable, non-culprit plaques, as long as subjects have no diagnosed CVD condition.